Mosaic Pattern of H3 K27M-Mutant Protein Expression in a Diffuse Midline Glioma—A Diagnostic Dilemma for the Pathologist

Deepti Narasimhaiah1  Bejoy Thomas2  Mathew Abraham3  Rajalakshmi Poyuran1

1Department of Pathology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
2Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India
3Department of Neurosurgery, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India

Abstract Diffuse midline glioma, H3 K27M-mutant, is a World Health Organization (WHO) grade IV glioma arising in pons, thalamus, and spinal cord. They show mutations resulting in replacement of lysine at position 27 by methionine (K27M) of histone genes, H3F3A, HIST1H3B, and HIST1H3C. The H3 K27M mutant protein is identified in tumor tissue by immunohistochemistry. As these mutations are clonal and homogeneous, the mutant protein is normally identified in all tumor cells. Here we report a case of diffuse midline glioma with mosaic pattern of expression of H3 K27M mutant protein and discuss the diagnostic and therapeutic implications of this unusual pattern.

Keywords glioma  H3 K27M  midline  mosaic

Introduction Diffuse midline glioma, H3 K27M-mutant, is a novel entity described in the 2016 World Health Organization (WHO) classification of tumors of the central nervous system that correspond to WHO grade IV. In this report, we present a rare case of diffuse midline glioma with a mosaic pattern of expression of H3 K27M-mutant protein.

Case History A 34-year-old lady presented with left-sided progressive weakness for the last 2 months; magnetic resonance imaging of brain revealed a 2.7 x 1.9 x 2.6 cm solid and cystic tumor involving the right thalamus and upper brainstem with a region of necrosis (Fig. 1A). There was peripheral contrast enhancement (Fig. 1B) with associated diffusion restriction and blooming. The patient underwent gross total resection of the tumor.

Histopathological examination revealed a high-grade astrocytoma (Fig. 1C, D). The tumor cells were positive for OLIG2 (Fig. 1E) and negative for R132H-mutant IDH1 (Fig. 1F). There was loss of nuclear expression for ATRX (Fig. 1G) and few nuclei expressed p53. The MIB-1 labeling index was 15% (Fig. 1H). K27M-mutant H3 was expressed by small clusters and single tumor cells (Fig. 1J), and endothelial cells were negative. Based on these morphological features, a diagnosis of glioblastoma, not otherwise specified, WHO grade IV, with a comment regarding the staining pattern of H3 K27M mutant protein, was rendered. Sequencing for IDH1/2, H3F3A, HIST1H3B, and HIST1H3C genes could not be performed.
Discussion

Diffuse midline gliomas from pons, thalamus, and spinal cord show mutations resulting in replacement of lysine at position 27 by methionine (K27M) of histone genes, H3F3A, HIST1H3B, and HIST1H3C.1-3 Within the brain, these mutations occur exclusively in midline gliomas. The histone mutations are associated with mutations in genes involved in cell cycle
regulation (TP53, PPM1D), chromatin remodeling (ATRX), and growth factors (ACVR1). These oncohistone mutations are considered to be initial genetic events in diffuse midline gliomas. They are clonal and homogeneous with high allelic frequency resulting in their presence in all tumor cells.

In routine histopathology practice, the histone mutations in diffuse midline gliomas are identified by immunohistochemistry using antibodies against H3 K27M mutant protein. The mutational homogeneity is reflected in the uniform staining of majority of tumor cell nuclei by H3 K27M mutant protein.

The mosaic pattern of staining for K27M-mutant H3 antibody in diffuse midline gliomas is an uncommon occurrence. The two cases reported by Lopez, et al, were diffuse midline gliomas histologically corresponding to WHO grade IV and III, respectively, harboring H3F3A K27M mutations at subclonal allele frequency. This was reflected in immunostaining of only some tumor cells for H3 K27M mutant protein.

The mosaic pattern of staining for H3 K27M mutant protein in diffuse midline gliomas raises questions regarding grading and classification for pathologists. First, what WHO grade should be assigned for a diffuse midline glioma demonstrating patchy staining for H3 K27M mutant protein and low-grade histologic features? Second, should these tumors be classified as “Diffuse midline glioma, H3 K27M-mutant”?

One clinical trial (https://clinicaltrials.gov/ct2/show/NCT02960230) is assessing the utility of synthetic peptide vaccine specific for the H3.3.K27M epitope with nivolumab in diffuse midline gliomas. In view of these novel strategies, the mosaic, subclonal pattern of H3 K27M mutation could have therapeutic implications.

In conclusion, we report a rare diffuse midline glioma with mosaic pattern of H3 K27M mutant protein expression and discuss the diagnostic and therapeutic implications.

Funding
None.

Conflict of Interest
None declared.

References